Literature DB >> 8810948

Production and characterisation of monoclonal antibodies to Brucella melitensis cytosoluble proteins that are able to differentiate antibody responses of infected sheep from Rev. 1 vaccinated sheep.

A Cloeckaert1, H S Debbarh, M S Zygmunt, G Dubray.   

Abstract

Monoclonal antibodies (MAbs) were produced to Brucella melitensis cytosoluble proteins (CP) with apparent molecular masses of 12, 24 and 28 kDa (CP12, CP24 and CP28) which were previously shown by immunoblotting to differentiate antibody responses of infected sheep from those of B. melitensis strain Rev. 1 vaccinated sheep. These MAbs were derived from mice infected with virulent smooth (S) B. melitensis strain H38. Most MAbs obtained were directed to CP28, which indicated (as was shown in infected sheep) that this protein was also highly immunogenic in mice. A large number of MAbs that showed reactivity to CP in ELISA but did not show reactivity in immunoblotting of CP were also obtained and might recognise conformational epitopes of these proteins. MAbs were used to localise CP12, CP24 and CP28. None of the MAbs reacted with whole B. melitensis cells in ELISA but showed reactivity with sonicated bacteria in ELISA, which indicated an internal localisation of these proteins. Among several B. melitensis B115 subcellular fractions tested, the anti-CP12 and anti-CP28 MAbs reacted essentially with the CP extract (CPE) in both ELISA and immunoblotting, whereas the anti-CP24 MAbs reacted with both CPE and cell envelope fraction (CEF)-although with lower intensity to the latter fraction. The internal localisation of these proteins was confirmed by immuno-electron microscopy of thin-sectioned B. melitensis B115 or B. melitensis 16M cells. Immunogold labelling was mainly observed in the cytoplasm and, consequently, CP12, CP24 and CP28 are probably cytoplasmic proteins. Immunoblotting of whole cell lysates with the MAbs also showed the presence of these proteins in all Brucella species and biovars, including the vaccine strains B. melitensis Rev. 1 and B. abortus B19. The use of these MAbs should help further study of antibody responses in sheep and other hosts and may be of considerable value for developing new diagnostic tests for ovine brucellosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8810948     DOI: 10.1099/00222615-45-3-206

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  9 in total

1.  Effect of early antibiotic treatment on the antibody response to cytoplasmic proteins of Brucella melitensis in mice.

Authors:  R A Bowden; G C Racaro; P C Baldi
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  Cloning, nucleotide sequence, and expression of the gene coding for a ribosome releasing factor-homologous protein of Brucella melitensis.

Authors:  N Vizcaíno; A Cloeckaert; G Dubray; M S Zygmunt
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

3.  Use of recombinant BP26 protein in serological diagnosis of Brucella melitensis infection in sheep.

Authors:  A Cloeckaert; S Baucheron; N Vizcaino; M S Zygmunt
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

4.  Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis.

Authors:  V K Gupta; G Radhakrishnan; J Harms; G Splitter
Journal:  Vaccine       Date:  2012-04-28       Impact factor: 3.641

5.  Diagnostic usefulness of antibodies against ribosome recycling factor from Brucella melitensis in human or canine brucellosis.

Authors:  Juliana Cassataro; M Victoria Delpino; Carlos A Velikovsky; Laura Bruno; Carlos A Fossati; Pablo C Baldi
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

6.  Epitope mapping of the Brucella melitensis BP26 immunogenic protein: usefulness for diagnosis of sheep brucellosis.

Authors:  Patricia Seco-Mediavilla; Jean-Michel Verger; Maggy Grayon; Axel Cloeckaert; Clara M Marín; Michel S Zygmunt; Luis Fernández-Lago; Nieves Vizcaíno
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

7.  Development and characterization of monoclonal antibodies and aptamers against major antigens of Mycobacterium avium subsp. paratuberculosis.

Authors:  John P Bannantine; Thomas J Radosevich; Judith R Stabel; Srinand Sreevatsan; Vivek Kapur; Michael L Paustian
Journal:  Clin Vaccine Immunol       Date:  2007-03-07

8.  In silico analysis of chimeric TF, Omp31 and BP26 fragments of Brucella melitensis for development of a multi subunit vaccine candidate.

Authors:  Amir Ghasemi; Reza Ranjbar; Jafar Amani
Journal:  Iran J Basic Med Sci       Date:  2014-03       Impact factor: 2.699

9.  Characterization of Cell Envelope Multiple Mutants of Brucella ovis and Assessment in Mice of Their Vaccine Potential.

Authors:  Rebeca Singh Sidhu-Muñoz; Pilar Sancho; Axel Cloeckaert; Michel Stanislas Zygmunt; María Jesús de Miguel; Carmen Tejedor; Nieves Vizcaíno
Journal:  Front Microbiol       Date:  2018-09-20       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.